Oxandrolone Anavar/Var

Anonymous

Oxandrolone - Anavar (Oxandrolone)

DESCRIPTION

Searle Company introduced the substance oxandrolone to the North American market in 1964 under the name Anavar and it enjoyed great popularity for over two decades until, on July 1, 1989, the production of Anavar was phased out. Today Anavar is manufactured under its various generic names in only a few countries. The compound with the generic name Oxandrolone SPA by S.P.A. Milano Company (Societ Prodotti Antibiotica) from Italy is the only original anabolic steroid available in Europe, which contains the substance oxandrolone. There are 30 tablets in one box with two push through strips of 15 tablets each. Oxandrolone is a weak steroid with only a slight androgenic component. It has been shown that Oxandrolone, when taken in reasonable dosages, rarely has any side effects. This is appreciated since Oxandrolone was developed mostly for women and children. Oxandrolone is one of the few steroids, which does not cause an early stunting of growth in children since it does not prematurely close the epiphysial growth plates. For this reason Oxandrolone is mostly used in children to stimulate growth and in women to prevent osteoporosis. Oxandrolone causes very light virilization symptoms, if at all. This characteristic makes Oxandrolone a favored remedy for female athletes since, at a daily dose of 10-15 mg, masculinizing symptoms are observed only rarely.

Bodybuilders and powerlifters, in particular, like Oxandrolone for three reasons. First, Oxandrolone causes a strong strength gain by stimulating the phosphocreatine synthesis in the muscle cell without depositing liquid (water) in the joints and the muscles. Power lifters and weightlifters who do not want to end up in a higher weight class take advantage of this since it allows them to get stronger without gaining body weight at the same time. The combination of Oxandrolone and 20 - 30 mg Halotestin daily has proven to be very effective since the muscles also look harder. Similarly good results can be achieved by a simultaneous intake of Oxandrolone and 120-140 mcg Clenbuterol per day. Although Oxandrolone itself does not cause a noticeable muscle growth it can clearly improve the muscle-developing effect of many steroids. Deca-Durabolin, Dianabol, and the various testosterone compounds, in particular, combine well with Oxandrolone to achieve a "mass buildup" because the strength gain caused by the intake of these highly tissue developing and liquid-retaining substances results in an additional muscle mass. A stack of 200 mg Deca-Durabolin/week, 500 mg Testosterone Enanthate (e.g. Testoviron Depot 250)/week, and 25 mg Oxandrolone/day leads to a good gain in strength and mass in most athletes. Deca-Durabolin has a distinct anabolic effect and stimulates the synthesis of protein; Oxandrolone improves the strength by a higher phosphocreatine synthesis; and Testosterone Enanthate increases the aggressiveness for the workout and accelerates regeneration.

The second reason why Oxandrolone is so popular is that this compound does not aromatize in any dosage. As already mentioned, a certain part of the testosterone present in the body is converted into estrogen. This aromatization process, depending on the predisposition, can vary distinctly from one athlete to another. Oxandrolone is one of the few steroids, which cannot aromatize to estrogen. This characteristic has various advantages for the athlete. With Oxandrolone the muscle system does not get the typical watery appearance as with many steroids, thus making it very interesting during the preparation for a competition. In this phase it is especially important to keep the estrogen level as low as possible since estrogen programs the body to store water even if the diet is calorie-reduced. In combination with a diet, Oxandrolone helps to make the muscles hard and ripped. Although Oxandrolone itself does not break down fat, it plays an indirect role in this process because the substance often suppresses the athlete's appetite. Oxandrolone can also cause some bloating, which in several athletes, results in nausea and vomiting when the tablets are taken with meals. The package insert of the Italian Oxandrolone notes its effect on the activity of the gastrointestinal tract. Some athletes thus report continued diarrhea. Although these symptoms are not very pleasant they still help the athlete break down fat and become harder. Those who work out for a competition or are interested in gaining quality muscles should combine Oxandrolone with steroids such as Winstrol, Parabolan, Masteron, Primobolan, and Testosterone Propionate. A stack of 50 mg Winstrol every two days, 50 mg Testosterone Propionate every two days, and 25 mg Oxandrolone every day has proven effective. Another advantage of Oxandrolone's non-aromatization is that athletes who suffer from high blood pressure or develop gynecomastia of the thymus glands when taking stronger androgenic steroids will not have these side effects with this compound. The. Oxandrolone/Deca-Durabolin stack is a welcome alternative for this group of athletes or for athletes showing signs of poor health during mass buildup with testosterone, Dianabol, or Anadrol 50. Athletes over forty should predominantly use Oxandrolone.

The third reason which speaks well for an intake of Oxandrolone is that even in a very high dosage this compound does not influence the body's own testosterone production. To make this clear: Oxandrolone does not suppress the body's own hormone production. The reason is that it does not have a negative feedback mechanism on the hypothalamohypophysial testicular axis, meaning that during the intake of Oxandrolone, unlike during the intake of most anabolic steroids, the testes signal the hypothalamus not to reduce or to stop the release of GnRH (gonadotropin releasing hormone) and LHRH Luteinizing hormone releasing hormone). This special feature of Oxandrolone can be explained by the fact that the substance is not converted into estrogen Oxandrolone (Anavar), when given to normal men in high doses does not reduce the seminal volume or count, nor can it be converted (aromatized) into estrogen.

DOSAGE

As for the dosage of Oxandrolone, 8-12 tablets in men and 5-6 tablets in women seem to bring the best results. The rule of thumb to take 0.125 mg/pound of body weight daily has proven successful in clinical tests. The tablets are normally taken two to three times daily after meals thus assuring an optimal absorption of the substance. Those who get the already discussed gastrointestinal pain when taking Oxandrolone are better off taking the tablets one to two hours after a meal or switching to another compound.

Since Oxandrolone is only slightly toxic and usually shows few side effects, several athletes use it over a prolonged period of time. However Oxandrolone should not be taken for several consecutive months, since, as with almost all oral steroids it is 1 7-alpha alkylated and thus liver toxic. Oxandrolone is an all purpose remedy, which depending on the athlete's goal is very versatile.

WOMEN

Women who react sensitively to the intake of anabolic steroids achieve good results when combining Oxandrolone/Primobolan Tabs and/or Clenbuterol, without suffering from the usual virilization symptoms. Women, however, should not take more than 6 tablets daily otherwise, androgenic-caused side effects such as acne, deep voice, clitorial hypertrophy or increased growth of body hair can occur.

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.

Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.

OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means.

DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL).

MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters.

RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was signi, Klemperer M, Morris J, Partington C, Tulley R.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.

OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means.

DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL).

MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters.

RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters.

CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were dueficantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters.

CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat

Researched by queenofdamned CJM